Skip to content

CninMed – China Innovative Drugs Update

  • China Pharma/Biotech Company
  • Contact Us
  • Web

Web

Fiercepharma https://www.fiercepharma.com/

BioCentury biocentury.com

Medscape

STAT

DDW https://www.ddw-online.com/

Recent Posts

  • [China BD 2026]
  • [China BD 2025] GeneScience and Yarrow Bioscience (RTW) Entered a 1.4 Billion USD License for Anti-TSHR Antibody GenSci098 (YB-101)
  • [China BD 2025] Fosun Pharma’s Subsidiary Yao Pharma and Pfizer Enter into a 2 Billion USD License on GLP-1R Agonists YP05002
  • [China BD 2025] Kelun-Biotech and Crescent Biopharma enter License and Collaboration on ITGB6 ADC SKB105 (CR-003)
  • [China BD 2025] Degron Therapeutics and MSD enters a License on FIC Molecular Glue Degraders

Recent Comments

  1. [China BD 2024] [China Biotech M&A] Biotheus and BioNTech Enters an Acquisition on PD-L1/VEGF-A BsAbs PM8002 (BNT327) – CninMed – China Innovative Drugs Update on [China BD 2023] Biotheus and BioNTech Enters the License on PD-L1/VEGF-A BsAbs PM8002 (BNT327)
  2. [Technology Collaboration] MediLink and BioNTech Expand the Collaboration on several ADC products – CninMed – China Innovative Drugs Update on [China BD 2023] MediLink and BioNTech enters a 1 billion USD License on HER3 ADC YL202 (BNT326)
  3. [China Original Asset] BioNTech and BMS enters a 11.1 billion USD Collaboration on PD-L1xVEGF-A BsAbs BNT327 (PM8002 from Biotheus) – CninMed – China Innovative Drugs Update on [China BD 2024] [China Biotech M&A] Biotheus and BioNTech Enters an Acquisition on PD-L1/VEGF-A BsAbs PM8002 (BNT327)
  4. admin on [China BD Deal] TUL and Novo Nordisk enters a 2 billion USD license for UBT251, a GLP-1/GIP/glucagon triple receptor agonist

Categories

  • China Biotech M&A
  • China FIC Drug
  • China License Out
  • China New Drug
  • China NewCo
  • China Original Asset
  • China Tech Corp
Copyright © 2026 CninMed - China Innovative Drugs Update.
Powered by WordPress and HybridMag.
  • China Pharma/Biotech Company
  • Contact Us
  • Web